# Concerto Biosciences

> Concerto Biosciences is a Cambridge, Massachusetts microbiome company that turns microbial ecology into health products. Its patented kChip platform screens millions of microbial interactions in nanoliter droplets to discover 'ensembles' - small, defined groups of microbes that work together to shepherd a damaged microbial community back to health. The company's lead program, ENS-002, is a topical live biotherapeutic for atopic dermatitis that suppresses Staphylococcus aureus without nuking the skin's helpful microbes. Founded in 2020 by scientists out of MIT and the Broad Institute, Concerto pairs ultra-high-throughput biology with AI to make microbial communities predictable and engineerable.

- **Founded:** 2020
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Cheri Ackerman (Co-Founder & CEO), Jared Kehe (Co-Founder & Chief Scientific Officer (inventor of kChip)), Bernardo Cervantes (Co-Founder), Adil Bahalim (Co-Founder)
- **Team size:** ~27 employees
- **Products:** kChip, kAI, ENS-002 (Fermata Derm), ENS-003, Consumer skin-health ingredients
- **Notable:** Measured over 6 million microbial interactions on its kChip platform, Raised $23M Series A in 2022 led by Safar Partners with Horizons Ventures and M Ventures, Positive Phase 1b topline results for ENS-002 in atopic dermatitis (2025) with no drug-related adverse events

## Products & services

- **kChip** — A patented ultra-high-throughput screening platform using nanoliter droplets and microwell arrays to measure millions of microbial interactions and map the interaction networks that reveal beneficial microbial communities.
- **kAI** — An AI/machine-learning layer that learns from kChip's structured ecological datasets to model microbial interactions and predict community behavior.
- **ENS-002 (Fermata Derm)** — A topical three-strain live biotherapeutic for mild-to-moderate atopic dermatitis (eczema) that suppresses Staphylococcus aureus while sparing beneficial skin microbes. Posted positive Phase 1b topline results in 2025.
- **ENS-003** — An ensemble in development targeting vaginal yeast infections / vaginal health.
- **Consumer skin-health ingredients** — Microbe-based ingredients and ensembles developed for consumer skin health, including B2B partnerships to embed Concerto's discoveries into other companies' products.

## Achievements

- Measured over 6 million microbial interactions on its kChip platform
- Raised $23M Series A in 2022 led by Safar Partners with Horizons Ventures and M Ventures
- Positive Phase 1b topline results for ENS-002 in atopic dermatitis (2025) with no drug-related adverse events
- CEO Cheri Ackerman named an EY Entrepreneur Of The Year 2023 New England finalist
- Licensed and commercialized kChip technology invented at MIT and the Broad Institute

## Latest updates

- **2025-10** — Announced positive topline results from the first-in-human Phase 1b trial of ENS-002 in atopic dermatitis: safe and well-tolerated, eczema symptoms improved, and S. aureus suppressed without disturbing beneficial microbes.
- **2023-06** — Co-founder and CEO Cheri Ackerman named an Ernst & Young Entrepreneur Of The Year 2023 New England finalist.
- **2022-11** — Closed a $23M Series A led by Safar Partners to advance ENS-002 toward first-in-human studies and expand the product pipeline.

## Links

- Website: https://concertobio.com
- LinkedIn: https://www.linkedin.com/company/concerto-biosciences
- Twitter/X: https://twitter.com/concertobio

---

Profile page: https://yespress.io/concerto-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-06-15